A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.
Carlsson
Stefan C
SC
AstraZeneca R&D Mölndal, Mölndal, Sweden. Stefan.c.carlsson@astrazeneca.com
Mattsson
Christer
C
Eriksson
Ulf G
UG
Sarich
Troy C
TC
Wåhlander
Karin
K
Eliasson
Asa
A
Karlson
Björn W
BW
Sheth
Sunita B
SB
Held
Peter
P
D001384:Azetidines / Q000494:pharmacology*; D001596:Benzylamines; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020128:Inhibitory Concentration 50
D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran